Surmodics FY2025 EPS Estimate Raised by Barrington Research

Surmodics, Inc. (NASDAQ:SRDX) – Analysts at Barrington Research boosted their FY2025 earnings estimates for Surmodics in a research note issued on Monday, August 11th. Barrington Research analyst M. Petusky now forecasts that the company will post earnings of ($0.30) per share for the year, up from their previous forecast of ($0.57). Barrington Research has a “Market Perform” rating on the stock. The consensus estimate for Surmodics’ current full-year earnings is $0.20 per share. Barrington Research also issued estimates for Surmodics’ Q4 2025 earnings at ($0.19) EPS and FY2026 earnings at ($0.12) EPS.

Separately, Needham & Company LLC reissued a “hold” rating on shares of Surmodics in a research report on Wednesday, April 30th.

Surmodics Stock Up 0.2%

Shares of NASDAQ SRDX opened at $37.99 on Wednesday. The company has a quick ratio of 3.10, a current ratio of 3.91 and a debt-to-equity ratio of 0.27. Surmodics has a 52 week low of $26.00 and a 52 week high of $40.38. The firm’s fifty day moving average is $31.77 and its 200 day moving average is $30.88. The company has a market cap of $543.18 million, a price-to-earnings ratio of -30.89 and a beta of 1.31.

Surmodics (NASDAQ:SRDX) last issued its earnings results on Friday, August 8th. The company reported $0.06 EPS for the quarter, topping the consensus estimate of ($0.21) by $0.27. Surmodics had a negative net margin of 14.59% and a negative return on equity of 2.99%. The company had revenue of $29.57 million for the quarter, compared to the consensus estimate of $28.04 million.

Institutional Investors Weigh In On Surmodics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Russell Investments Group Ltd. increased its holdings in Surmodics by 705.9% in the 2nd quarter. Russell Investments Group Ltd. now owns 1,233 shares of the company’s stock worth $37,000 after acquiring an additional 1,080 shares in the last quarter. Strs Ohio purchased a new stake in Surmodics in the 1st quarter worth approximately $122,000. Legal & General Group Plc increased its holdings in Surmodics by 34.2% in the 4th quarter. Legal & General Group Plc now owns 3,452 shares of the company’s stock worth $137,000 after acquiring an additional 880 shares in the last quarter. Price T Rowe Associates Inc. MD purchased a new stake in Surmodics in the 4th quarter worth approximately $217,000. Finally, AlphaQuest LLC purchased a new stake in Surmodics in the 1st quarter worth approximately $232,000. Hedge funds and other institutional investors own 96.63% of the company’s stock.

Surmodics Company Profile

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).